These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

327 related items for PubMed ID: 26189429

  • 1. Expression of angiogenic switch, cachexia and inflammation factors at the crossroad in undifferentiated thyroid carcinoma with BRAF(V600E).
    Husain A, Hu N, Sadow PM, Nucera C.
    Cancer Lett; 2016 Oct 01; 380(2):577-585. PubMed ID: 26189429
    [Abstract] [Full Text] [Related]

  • 2. Metastasis-associated MCL1 and P16 copy number alterations dictate resistance to vemurafenib in a BRAFV600E patient-derived papillary thyroid carcinoma preclinical model.
    Duquette M, Sadow PM, Husain A, Sims JN, Antonello ZA, Fischer AH, Song C, Castellanos-Rizaldos E, Makrigiorgos GM, Kurebayashi J, Nose V, Van Hummelen P, Bronson RT, Vinco M, Giordano TJ, Dias-Santagata D, Pandolfi PP, Nucera C.
    Oncotarget; 2015 Dec 15; 6(40):42445-67. PubMed ID: 26636651
    [Abstract] [Full Text] [Related]

  • 3. Combination BRAFV600E Inhibition with the Multitargeting Tyrosine Kinase Inhibitor Axitinib Shows Additive Anticancer Activity in BRAFV600E-Mutant Anaplastic Thyroid Cancer.
    Gunda V, Ghosh C, Hu J, Zhang L, Zhang YQ, Shen M, Kebebew E.
    Thyroid; 2023 Oct 15; 33(10):1201-1214. PubMed ID: 37675898
    [Abstract] [Full Text] [Related]

  • 4. Combination Treatment with the BRAFV600E Inhibitor Vemurafenib and the BH3 Mimetic Navitoclax for BRAF-Mutant Thyroid Carcinoma.
    Jeong JH, Oh JM, Jeong SY, Lee SW, Lee J, Ahn BC.
    Thyroid; 2019 Apr 15; 29(4):540-548. PubMed ID: 30869573
    [Abstract] [Full Text] [Related]

  • 5. CLM29 and CLM24, pyrazolopyrimidine derivatives, have antitumoral activity in vitro in anaplastic thyroid cancer, with or without BRAF mutation.
    Fallahi P, Ferrari SM, La Motta C, Materazzi G, Bocci G, Da Settimo F, Miccoli P, Antonelli A.
    Endocrine; 2016 Jul 15; 53(1):136-44. PubMed ID: 26286966
    [Abstract] [Full Text] [Related]

  • 6. S100A4 Knockout Sensitizes Anaplastic Thyroid Carcinoma Cells Harboring BRAFV600E/Mt to Vemurafenib.
    Jiao X, Zhang H, Xu X, Yu Y, Zhang H, Zhang J, Ning L, Hao F, Liu X, Niu M, Chen CT, Chen D, Zhang K.
    Cell Physiol Biochem; 2018 Jul 15; 49(3):1143-1162. PubMed ID: 30196299
    [Abstract] [Full Text] [Related]

  • 7. Fine-Tuning Lipid Metabolism by Targeting Mitochondria-Associated Acetyl-CoA-Carboxylase 2 in BRAFV600E Papillary Thyroid Carcinoma.
    Valvo V, Iesato A, Kavanagh TR, Priolo C, Zsengeller Z, Pontecorvi A, Stillman IE, Burke SD, Liu X, Nucera C.
    Thyroid; 2021 Sep 15; 31(9):1335-1358. PubMed ID: 33107403
    [Abstract] [Full Text] [Related]

  • 8. Late intervention with anti-BRAF(V600E) therapy induces tumor regression in an orthotopic mouse model of human anaplastic thyroid cancer.
    Nehs MA, Nucera C, Nagarkatti SS, Sadow PM, Morales-Garcia D, Hodin RA, Parangi S.
    Endocrinology; 2012 Feb 15; 153(2):985-94. PubMed ID: 22202162
    [Abstract] [Full Text] [Related]

  • 9. Autophagy sustains mitochondrial respiration and determines resistance to BRAFV600E inhibition in thyroid carcinoma cells.
    Díaz-Gago S, Vicente-Gutiérrez J, Ruiz-Rodríguez JM, Calafell J, Álvarez-Álvarez A, Lasa M, Chiloeches A, Baquero P.
    Autophagy; 2024 Jun 15; 20(6):1383-1397. PubMed ID: 38436206
    [Abstract] [Full Text] [Related]

  • 10. Signal transducer and activator of transcription 3 inhibition alleviates resistance to BRAF inhibition in anaplastic thyroid cancer.
    Wang Y, Hu Z, Ma W, Niu Y, Su J, Zhang L, Zhao P.
    Invest New Drugs; 2021 Jun 15; 39(3):764-774. PubMed ID: 33245464
    [Abstract] [Full Text] [Related]

  • 11. Long-term vemurafenib treatment drives inhibitor resistance through a spontaneous KRAS G12D mutation in a BRAF V600E papillary thyroid carcinoma model.
    Danysh BP, Rieger EY, Sinha DK, Evers CV, Cote GJ, Cabanillas ME, Hofmann MC.
    Oncotarget; 2016 May 24; 7(21):30907-23. PubMed ID: 27127178
    [Abstract] [Full Text] [Related]

  • 12. Targeting PEAK1 sensitizes anaplastic thyroid carcinoma cells harboring BRAFV600E to Vemurafenib by Bim upregulation.
    Wang Q, Hao F, Ning L, Sun C.
    Histol Histopathol; 2024 Sep 24; 39(9):1159-1165. PubMed ID: 38284248
    [Abstract] [Full Text] [Related]

  • 13. Role of BRAFV600E in the first preclinical model of multifocal infiltrating myopericytoma development and microenvironment.
    Sadow PM, Priolo C, Nanni S, Karreth FA, Duquette M, Martinelli R, Husain A, Clohessy J, Kutzner H, Mentzel T, Carman CV, Farsetti A, Henske EP, Palescandolo E, Macconaill LE, Chung S, Fadda G, Lombardi CP, De Angelis AM, Durante O, Parker JA, Pontecorvi A, Dvorak HF, Fletcher C, Pandolfi PP, Lawler J, Nucera C.
    J Natl Cancer Inst; 2014 Aug 24; 106(8):. PubMed ID: 25063326
    [Abstract] [Full Text] [Related]

  • 14. The Tyrosine Kinase Inhibitor Lenvatinib Inhibits Anaplastic Thyroid Carcinoma Growth by Targeting Pericytes in the Tumor Microenvironment.
    Iesato A, Li S, Sadow PM, Abbasian M, Nazarian A, Lawler J, Nucera C.
    Thyroid; 2023 Jul 24; 33(7):835-848. PubMed ID: 37171127
    [Abstract] [Full Text] [Related]

  • 15. Sorafenib inhibits vascular endothelial cell proliferation stimulated by anaplastic thyroid cancer cells regardless of BRAF mutation status.
    Ishihara S, Onoda N, Noda S, Asano Y, Tauchi Y, Morisaki T, Kashiwagi S, Takashima T, Ohira M.
    Int J Oncol; 2019 Nov 24; 55(5):1069-1076. PubMed ID: 31545405
    [Abstract] [Full Text] [Related]

  • 16. A Phase 2 Study of Encorafenib in Combination with Binimetinib in Patients with Metastatic BRAF-Mutated Thyroid Cancer in Japan.
    Tahara M, Kiyota N, Imai H, Takahashi S, Nishiyama A, Tamura S, Shimizu Y, Kadowaki S, Ito KI, Toyoshima M, Hirashima Y, Ueno S, Sugitani I.
    Thyroid; 2024 Apr 24; 34(4):467-476. PubMed ID: 38343359
    [Abstract] [Full Text] [Related]

  • 17. Activating BRAF and PIK3CA mutations cooperate to promote anaplastic thyroid carcinogenesis.
    Charles RP, Silva J, Iezza G, Phillips WA, McMahon M.
    Mol Cancer Res; 2014 Jul 24; 12(7):979-86. PubMed ID: 24770869
    [Abstract] [Full Text] [Related]

  • 18. Complete Surgical Resection Following Neoadjuvant Dabrafenib Plus Trametinib in BRAFV600E-Mutated Anaplastic Thyroid Carcinoma.
    Wang JR, Zafereo ME, Dadu R, Ferrarotto R, Busaidy NL, Lu C, Ahmed S, Gule-Monroe MK, Williams MD, Sturgis EM, Goepfert RP, Gross ND, Lai SY, Gunn GB, Phan J, Rosenthal DI, Fuller CD, Morrison WH, Iyer P, Cabanillas ME.
    Thyroid; 2019 Aug 24; 29(8):1036-1043. PubMed ID: 31319771
    [Abstract] [Full Text] [Related]

  • 19. BRAF Inhibition in BRAFV600E-Positive Anaplastic Thyroid Carcinoma.
    Lim AM, Taylor GR, Fellowes A, Cameron L, Lee B, Hicks RJ, McArthur GA, Angel C, Solomon B, Rischin D.
    J Natl Compr Canc Netw; 2016 Mar 24; 14(3):249-54. PubMed ID: 26957611
    [Abstract] [Full Text] [Related]

  • 20. BRAF(V600E) mutation and expression of proangiogenic molecular markers in papillary thyroid carcinomas.
    Durante C, Tallini G, Puxeddu E, Sponziello M, Moretti S, Ligorio C, Cavaliere A, Rhoden KJ, Verrienti A, Maranghi M, Giacomelli L, Russo D, Filetti S.
    Eur J Endocrinol; 2011 Sep 24; 165(3):455-63. PubMed ID: 21653734
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.